000			nab a22 7a 4500
999			_c16348 _d16348
003			PC16348
005			20220226062801.0
008			210413b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_92644 _aVallet Regí, María _eInstituto de Investigación imas12
100			_92804 _aVila, M. _eInstituto de Investigación i+12
245	0	0	_aIn vitro evaluation of graphene oxide nanosheets on immune function _h[artículo]
260			_bJournal of colloid and interface science, _c2014
300			_a432:221-8.
500			_aFormato Vancouver: Feito MJ, Vila M, Matesanz MC, Linares J, Gonçalves G, Marques PA et al. In vitro evaluation of graphene oxide nanosheets on immune function. J Colloid Interface Sci. 2014 Oct 15;432:221-8.
501			_aPMID: 25086397
504			_aContiene 52 referencias
520			_aHypothesis: Graphene oxide (GO) has attracted the scientific community attention due to its novel properties and wide range of potential applications including hyperthermia cancer therapy. However, little is known about the GO effects on the immune function which involves both innate and adaptive defence mechanisms through the activation of different cell populations and secretion of several cytokines. The effect of different GO nanosheets designed for hyperthermia cancer therapy on macrophage and lymphocyte function should be determined before using GO for this application. Experiments: The effects of GO nanosheets with 1 (1-GOs) and 6 arms (6-GOs) of polyethylene glycol on RAW-264.7 macrophages and primary splenocytes (as approximation to the in vivo situation) were evaluated through the proinflammatory cytokine secretion and the modulation of cell proliferation in the presence of specific stimuli for either T-lymphocytes (concanavalin A, anti-CD3 antibody) or B-lymphocytes/macrophages (lipopolysaccharide). Findings: 6-GOs significantly increased the secretion of TNF-α by RAW-264.7 macrophages without alteration of IL-6 and IL-1β levels. The treatment of primary splenocytes with 1-GOs and 6-GOs in the presence of concanavalin A, anti-CD3 antibody and lipopolysaccharide, produced significant dose-dependent decreases of cell proliferation and IL-6 levels, revealing weak inflammatory properties of GOs which are favourable for hyperthermia cancer therapy.
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16348.pdf _ySolicitar documento
942			_2ddc _cART _n0